August 9th, 2022

A full text version of this article is available.
To access article obtain online access here or login
Long-Term Fetomaternal Outcomes After Fertility-Sparing Surgery in Malignant Ovarian Germ Cell Tumor Patients
Authors:  Qingyong Guo, M.D., Huan Yi, M.D., Xiangqin Zheng, M.D., Jianrong Song, B.D., Suyu Li, M.D., and Yuan Lin, M.D.
  OBJECTIVE: To clarify long-term maternal and fetal outcomes after fertility-sparing surgery in malignant ovarian germ cell tumor (MOGCT).

STUDY DESIGN: We conducted a retrospective review of MOGCT patients who received fertility-sparing surgery from January 2005 to December 2015 in our hospital. Demographic and clinical data were analyzed. Enrolled patients were followed up by telephone to collect maternal and fetal medical history.

RESULTS: A total of 27 patients with a mean age of 22 years were identified, and 85.2% received adjuvant chemotherapy. The mean follow-up period was 100.96 (47–157) months. No patients died, and 2 patients (7.4%) suffered recurrence. The pregnancy rate was 92.3%, and the live birth rate was 68.8%, including one of the patients with recurrence. The interval time between the last treatment to the first pregnancy was 38.67±18.69 months. The miscarriage rate was 12.5%, which is a little higher than that of the general population. There were no neonatal deformities or long-term physical and psychological disorders shown in the offspring.

CONCLUSION: Fertility-sparing surgery in MOGCT is safe and, followed by adjuvant chemotherapy, has little or no effect on fetomaternal long-term outcomes.
Keywords:  fertility, fertility-sparing surgery, germ cell cancer, malignant ovarian germ cell tumor, neonatal, ovarian cancer, ovarian germ cell tumor, ovarian neoplasms, prognosis, reproductive
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from